Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Price, News & Analysis

Cerevel Therapeutics logo

About Cerevel Therapeutics Stock (NASDAQ:CERE)

Advanced Chart

Key Stats

Today's Range
$44.96
$44.96
50-Day Range
$40.30
$44.96
52-Week Range
$19.59
$44.99
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$8.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

CERE Stock Analysis - Frequently Asked Questions

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), First Solar (FSLR) and Datadog (DDOG).

Company Calendar

Last Earnings
11/01/2023
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Current Symbol
NASDAQ:CERE
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-432,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.71 per share
Price / Book
12.12

Miscellaneous

Free Float
172,903,000
Market Cap
$8.19 billion
Optionable
Optionable
Beta
1.40

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:CERE) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners